Icons / Logo / Facebook Created with Sketch. Icons / Logo / Google Created with Sketch. Icons / Logo / ORCID Created with Sketch. Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Clare Fiala
Mount Sinai Hospital, Toronto
18Publications
3H-index
37Citations
Publications 18
Newest
Published in BMC Medicine 8.29
Clare Fiala3
Estimated H-index: 3
(MSH: Mount Sinai Hospital, Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
(U of T: University of Toronto)
Published on Jan 18, 2019in BMC Medicine 8.29
Clare Fiala3
Estimated H-index: 3
(Mount Sinai Hospital),
Eleftherios P. Diamandis97
Estimated H-index: 97
Where should I submit my paper? This is a question that young scientists and trainees frequently ask. In this Commentary, we advise on how to make such a decision whilst balancing the risks and benefits. We argue that trying to publish in top tier journals may not always be the best option and that publishing in indexed, open access journals may expose research to the same or larger audiences. The value of research should not be judged according to the publishing journal’s name, but rather from ...
Clare Fiala3
Estimated H-index: 3
,
Bryant Lim1
Estimated H-index: 1
,
Eleftherios P. Diamandis97
Estimated H-index: 97
Published in Clinical Biochemistry 2.43
Clare Fiala3
Estimated H-index: 3
(MSH: Mount Sinai Hospital, Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
(U of T: University of Toronto)
Published on Apr 17, 2019
Clare Fiala3
Estimated H-index: 3
(MSH: Mount Sinai Hospital, Toronto),
Jennifer Taher6
Estimated H-index: 6
(U of T: University of Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
(U of T: University of Toronto)
Background: The term P4 medicine (predictive, preventative, personalized, participatory) was coined by Dr. Leroy Hood of the Institute for Systems Biology to demonstrate his framework to detect and prevent disease through extensive biomarker testing, close monitoring, deep statistical analysis, and patient health coaching. Methods: In 2017, this group published the results of their “100 Person Wellness Project.” They performed whole genome sequencing and 218 clinical laboratory tests, measured 6...
Published on Mar 26, 2019in Clinical Chemistry and Laboratory Medicine 3.64
Clare Fiala3
Estimated H-index: 3
,
Jennifer Taher6
Estimated H-index: 6
,
Eleftherios P. Diamandis97
Estimated H-index: 97
Published on Dec 11, 2018in Clinical Chemistry and Laboratory Medicine 3.64
Clare Fiala3
Estimated H-index: 3
,
Eleftherios P. Diamandis97
Estimated H-index: 97
Published on Mar 1, 2019
Clare Fiala3
Estimated H-index: 3
(MSH: Mount Sinai Hospital, Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
(U of T: University of Toronto)
The biotechnology company Theranos has been consistently appearing across newspaper and magazine headlines over the past few years (1–3). In 2014, the firm's then 30-year-old founder, charismatic Stanford-dropout Elizabeth Holmes, began to receive tremendous amounts of media attention (1–4). She was trumpeted as a visionary as she proclaimed her plan to revolutionize blood testing (2). Her company garnered hundreds of millions of dollars following her claim that Theranos had designed a system to...
Published on Dec 1, 2018in BMC Medicine 8.29
Clare Fiala3
Estimated H-index: 3
(MSH: Mount Sinai Hospital, Toronto),
Eleftherios P. Diamandis97
Estimated H-index: 97
(U of T: University of Toronto)
Various recent studies have focused on analyzing tumor genetic material released into the blood stream, known as circulating tumor DNA (ctDNA). Herein, we describe current research on the application of ctDNA to cancer management, including prognosis determination, monitoring for treatment efficacy/relapse, treatment selection, and quantification of tumor size and disease burden. Specifically, we examine the utility of ctDNA for early cancer diagnostics focusing on the development of a blood tes...
12